How has the UK compared to its European peers in terms of supporting growth and innovation in the pharmaceutical sector? And with a renegotiation of the PPRS pricing deal imminent, Leela
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh